Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04098393
Other study ID # 19-245
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date September 18, 2019
Est. completion date September 2025

Study information

Verified date October 2023
Source Memorial Sloan Kettering Cancer Center
Contact Michael Scordo, MD
Phone 212-639-6052
Email ABMTTrials@mskcc.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to see if a condensed version of the chemotherapy regimen busulfan, melphalan, fludarabine (bu/mel/flu) and the drug antithymocyte globulin (ATG-also referred to as rATG or thymoglobulin) can have the same or fewer number of severe side effects in people with various blood cancers 30 days after they receive an allogeneic hematopoietic cell transplantation.


Recruitment information / eligibility

Status Recruiting
Enrollment 45
Est. completion date September 2025
Est. primary completion date September 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients aged = 18 years old. - Patients with any of the following hematologic malignancies for which allo-HCT is indicated, including: - Acute myeloid leukemia (AML) with intermediate or high-risk features in CR1. - Relapsed AML in = CR2. - Acute leukemias of ambiguous lineage in = CR1. - Acute lymphoid leukemia (ALL) in CR1 with clinical, flow cytometric, or molecular features indicating a high risk for relapse, or ALL in = CR2. - CML meeting one of the following criteria: - Failed response to or intolerant to BCR-ABL tyrosine kinase inhibitors (TKIs). - CML with BCR-ABL mutation consistent with poor response to TKIs (e.g., T315I mutation) - CML in accelerated phase or blast crisis with <10% blasts after therapy, or in second chronic phase. - Myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), or MDS/MPN overlap syndromes with least one of the following: - Revised International Prognostic Scoring System risk score of intermediate or higher at the time of transplant evaluation. - Life-threatening cytopenias. - Karyotype or genomic changes that indicate high risk for progression to acute myelogenous leukemia, including abnormalities of chromosome 7 or 3, mutations of TP53, or complex or monosomal karyotype. - Therapy related disease or disease evolving from other malignant processes. - Chronic myelomonocytic leukemia (CMML-1 or CMML-2). - Severe aplastic anemia. - Relapsed Hodgkin lymphoma meeting both of the following criteria: - Responding to therapy prior to enrollment. - Relapse after autologous HCT or are ineligible for autologous HCT. - Relapsed non-Hodgkin lymphoma meeting both of the following criteria: - Responding to therapy prior to enrollment. - Relapse after prior autologous HCT or are ineligible for autologous HCT. - High-risk multiple myeloma following autologous HCT or relapsed multiple myeloma following autologous HCT with chemosensitive disease. - Adequate organ function is required, defined as follows: - Serum bilirubin = 2 mg/dL, unless benign congenital hyperbilirubinemia. Patients with hyperbilirubinemia related to paroxysmal nocturnal hemoglobinuria or other hemolytic disorders are eligible with PI approval. - AST, ALT, and alkaline phosphatase < 3 times the upper limit of normal unless thought to be disease-related. - Creatinine clearance = 50 ml/min (calculated by Cockcroft Gault) - LVEF = 45% by MUGA or resting echocardiogram. - Pulmonary function (FEV1 and corrected DLCO) = 50% predicted. - Adequate performance status of ECOG = 2. - Each patient must be willing to participate as a research subject and must sign an informed consent form. Exclusion Criteria: - Patients with active extramedullary disease. - Patients with active central nervous system malignancy. - Active and/or uncontrolled infection at the time of allo-HCT. - Patients who have undergone previous allo-HCT. - Patients who have undergone previous autologous HCT within the last 6 months, with the exclusion of high-risk multiple myeloma patients. - Patient seropositivity for HIV I/II and/or HTLV I/II. - Females who are pregnant or breastfeeding. - Patients unwilling to use contraception during the study period. - Patient or guardian unable to give informed consent or unable to comply with the treatment protocol. Donor Inclusion and Exclusion Criteria: - Must be a 10/10 HLA genotypically matched related or unrelated donor at A, B, C, DRB1, and DQB1 loci, as tested by DNA analysis. - Able to provide informed consent for the donation process per institutional standards. - Meet standard criteria for donor collection as defined by the National Marrow Donor Program Guidelines.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Busulfan 3.2 mg/kg/day
Busulfan 3.2 mg/kg/day, with dose adjustments made according to pharmacokinetic (PK) levels.
Fludarabine
Fludarabine (25mg/m2/ day) administered on days -6, -5, -4, -3, and -2.
Melphalan
Melphalan (70mg/m2/day) administered on days -6 and -5.
Antithymocyte globulin (ATG)
ATG will be given based on a dynamic nomogram based on the patient's absolute lymphocyte count at the start of conditioning and can result in 2 or 3 days of ATG administration.
Busulfan 0.8 mg/kg
Busulfan 0.8 mg/kg every 6 hours x 10 doses, with dose adjustments made according to PK levels.
Procedure:
Allogeneic hematopoietic cell transplantation (Allo-HCT)
Allogeneic hematopoietic cell transplantation following the conditioning regimen.

Locations

Country Name City State
United States Memorial Sloan Kettering Cancer Center New York New York

Sponsors (1)

Lead Sponsor Collaborator
Memorial Sloan Kettering Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary the number of grade 4 toxicities All grade 4 CTCAEv5.0 toxicities are included except for hematologic toxicities that are considered expected for patients receiving myeloablative conditioning. in the first 30 days post-HCT
See also
  Status Clinical Trial Phase
Recruiting NCT05433090 - An Inpatient Advance Care Planning Intervention for Older Patients With Hematologic Malignancies N/A
Completed NCT00061620 - Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies Phase 1
Enrolling by invitation NCT02473757 - Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies
Not yet recruiting NCT06296368 - DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics N/A
Recruiting NCT02032446 - Umbilical Cord Derived Mesenchymal Stromal Cells For The Treatment of Severe Steroid-resistant Graft Versus Host Disease Phase 1/Phase 2
Recruiting NCT01203722 - Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies Phase 1/Phase 2
Recruiting NCT02884375 - Elderly CAncer Patient N/A
Completed NCT00780052 - Infusional C-myb ASODN in Advanced Hematologic Malignancies Phase 1
Recruiting NCT06028828 - Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation Phase 2
Completed NCT04538599 - RD13-01 for Patients With r/r CD7+ T/NK Cell Hematologic Malignancies Phase 1
Completed NCT03609827 - Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
Completed NCT01380756 - Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia Phase 1
Recruiting NCT05849207 - Post-Transplant Cyclophosphamide in Patients Aged >/= 70 Years Undergoing Haploidentical Transplant Phase 1
Not yet recruiting NCT05028478 - A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies Phase 1/Phase 2
Active, not recruiting NCT02494258 - A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders Phase 2
Completed NCT03212560 - Exercise Capacity and Physical Activity Levels in Newly Diagnosed Hematologic Malignant Patients
Active, not recruiting NCT02600208 - Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies With Alpha Beta TCell and B Cell Depletion Using the CliniMACS Device Phase 2/Phase 3
Completed NCT02145403 - Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies Phase 1/Phase 2
Completed NCT01949545 - Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment Phase 1
Completed NCT01930981 - Associations Between Pre-transplant Comorbidities and Post-transplant Toxicities and Quality of Life N/A